Understanding DARZALEX and DARZALEX FASPRO

Darzalex® (daratumumab) is the first monoclonal antibody approved by the FDA that targets the CD38 protein on the surface of myeloma cells, causing myeloma cell death. Darzalex Faspro® (daratumumab + hyaluronidase-fihj) is a newer formulation of this targeted therapy. There are numerous FDA-approved regimens with Darzalex or Darzalex Faspro that are used throughout the myeloma disease course - from frontline therapy to the relapsed and refractory setting - and many ongoing myeloma clinical trials are investigating additional indications.